

Novugen Wins Two Pharma Industry Awards at MOPI 45th Anniversary Dinner

Novugen is proud to have secured first place in two categories at the Pharma Industry Awards 2026, held in conjunction with the Malaysian Organisation of Pharmaceutical Industries (MOPI)'s 45th Anniversary Dinner.

The awards were presented to **Novugen's CEO, Rahil Mahmood**, by **YB Tuan Sim Tze Tzin, Deputy Minister of Investment, Trade and Industry (MITI)**, in recognition of our achievements in the following categories:

First Place: Highest R&D Investment (*R&D Investment to Total Sales 2025*)

We invested 31% of our total sales in R&D in 2025, reflecting our continued commitment to developing complex generics and first-to-market products for Malaysia, the U.S. and other emerging markets.



First Place: Fastest Export Sales Growth (*Export Sales Above RM50 Million: CAGR 2021–2025*)

Since establishing our presence in the U.S. in 2021, we have achieved an impressive 81% compound annual growth rate (CAGR) in U.S. sales, reflecting our progress towards becoming one of the fastest-growing generic pharmaceutical companies in the U.S. market.





These accolades underscore Novugen's commitment to challenging the status quo through scientific innovation, manufacturing excellence and sustainable growth. As we continue to break barriers in pharmaceutical development and expand our global reach, we remain driven by our mission to accelerate access to high-quality, affordable medicines worldwide.